Cardiac Resynchronization Therapy Market 2033: Japan and Europe Push High-Tech Implants
The global cardiac resynchronization therapy (CRT) market size was valued at USD 4.74 billion in 2024 and is expected to reach USD 8.21 billion by 2033, registering a CAGR of 6.3% from 2025 to 2033.
Cardiac Resynchronization Therapy Market Summary
The global cardiac resynchronization therapy (CRT) market size was valued at USD 4.74 billion in 2024 and is expected to reach USD 8.21 billion by 2033, registering a CAGR of 6.3% from 2025 to 2033. Growth is primarily driven by the increasing prevalence of heart failure and conduction abnormalities, rising adoption of advanced implantable cardiac devices, and expanding clinical evidence confirming the effectiveness of CRT in improving patient survival rates and overall quality of life.
Technological innovations—including conduction system pacing (CSP), left bundle branch area pacing (LBBAP), and next-generation leadless or wireless CRT systems—are improving device accuracy and reducing procedural risks, which is contributing to broader adoption among cardiologists. Favorable reimbursement structures, increasing awareness of early intervention for heart failure, and greater use of AI-enabled remote monitoring platforms are also supporting market expansion. Furthermore, continuous product advancements, including MRI-compatible models and Bluetooth-enabled CRT devices, are widening the patient pool eligible for CRT and strengthening the global market outlook.
The rising burden of cardiovascular diseases (CVDs) remains a significant catalyst for market growth. According to Oxford Academic (January 2025), the global age-standardized CVD prevalence stands at about 7,179 cases per 100,000 population, illustrating the ongoing global challenge posed by heart-related disorders. In the U.S., conditions such as heart failure and arrhythmias continue to escalate due to lifestyle-related factors including lack of physical activity, obesity, and metabolic disorders. Data from the American Heart Association (January 2024) shows 931,578 CVD-related deaths, reflecting an increase of nearly 3,000 from the previous year. The age-adjusted mortality rate also climbed by 4.0%, reaching 233.3 deaths per 100,000 population, highlighting an urgent need for effective cardiac management solutions such as CRT.
Order a free sample PDF of the Cardiac Resynchronization Therapy Market Intelligence Study, published by Grand View Research.
Key Market Trends & Insights
- North America dominated the global CRT market in 2024 with a 52.72% revenue share.
- The U.S. accounted for the largest share within the North American CRT market in 2024.
- By product, the CRT-defibrillator segment held the highest share at 55.04% in 2024.
- By end-use, hospitals represented the largest segment with a 49.20% revenue share in 2024.
Market Size & Forecast
- 2024 Market Size: USD 4.74 Billion
- 2033 Projected Market Size: USD 8.21 Billion
- CAGR (2025–2033): 6.3%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing regional market in 2024
Key Cardiac Resynchronization Therapy Company Insights
Major players such as Abbott, Biotronik, and Medtronic continue to strengthen their market position through strategic initiatives including mergers and acquisitions, collaborations, and expanded distribution networks. These activities enable wider market penetration, improved technology integration, and enhanced product portfolios. Meanwhile, emerging participants such as Schiller and MEDICO S.R.L. are accelerating innovation, expanding their regional presence, and forming new partnerships to better compete with well-established market leaders. Collectively, these strategic moves are shaping a highly competitive and technologically advanced CRT landscape.
Key Cardiac Resynchronization Therapy Companies
- Abbott
- Biotronik
- Medtronic
- Boston Scientific Corporation
- MicroPort Scientific Corporation
- OSYPKA MEDICAL
- MEDICO S.R.L.
- Schiller
Explore Horizon Databook - The world's most expansive market intelligence platform developed by Grand View Research .
Conclusion
The cardiac resynchronization therapy market is experiencing steady growth driven by rising CVD prevalence, rapid technological advancements, and improved accessibility to sophisticated implantable devices. With strong demand for early heart failure intervention, evolving pacing technologies, and enhanced remote monitoring capabilities, the market is expected to maintain its upward trajectory through 2033. Leading companies continue to drive innovation while new entrants contribute to heightened competition and expanded therapeutic options, ensuring a dynamic and evolving global CRT landscape.